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ABSTRACT 
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women. This disease 
is characterized by infertility, menstrual dysfunction, and hyperandrogenism. Also, PCOS is often associated 
with hyperlipidemia and impaired glucose tolerance, conditions that are associated with cardiovascular disorder, 
type 2 diabetes, cancer and hypertension. Evidence supports that some nutrients may affect the hormonal and 
metabolic disturbances of PCOS. Here in this study, we aimed to review the available literature that assessed the 
nutrients such as inostol, isoflavonids, resveratrol, vitamin D, and PUFA (polyunsaturated fatty acids), known to 
influence the hormonal and metabolic disturbances of PCOS, along with the strategies and future directions of 
nutrient supplementations in such patients.  
 
Keywords: Polycystic ovary syndrome, inositol, isoflavonids, resveratrol, vitamin D, PUFA 
 
Abbreviations: BMI: Body mass index; DHA: Docosahexaenoic acid; DHEAS: Dehydroepiandrostrone sulfate; 
DNA: Deoxyribonucleic acid; EPA: Eicosapentaenoic acid; FAI: Free androgen index; FSH: Follicle stimulating 
hormone; GPx: Glutathione peroxides; GSH: Glutathione; HbA1c: Glycosylated hemoglobin; IGT: Impaired 
glucose tolerance; IPG: Inositolphosphoglycans; LDL-C: Low-density lipoprotein cholesterol; LH: Luteinizing 
hormone; OGTT: Oral glucose tolerance test; PCOS: Polycystic ovary syndrome; ROS: Reactive oxygen spe-
cies; SOD: Superoxide dismutase; StAR: Steroidogenic acute regulatory; PPAR: Peroxisome proliferator-
activated receptor; PRL: Prolactin; PUFA: Polyunsaturated fatty acids; SHBG: Sex hormone binding protein; T-
l: Theca– interstitial; VEGF: Vascular endothelial growth factor  
 
 
 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is an 
endocrine disorder among women of repro-
ductive age, affecting 6-10 % of women of 
reproductive age (Sabuncu et al., 2001). This 
disease is clinically characterized by hyper-
androgenic nature, chronic lack of ovulation 
and/or polycystic ovaries (Baillargeon et al., 
EXCLI Journal 2016;15:551-564 – ISSN 1611-2156 
Received: June 01, 2016, accepted: August 02, 2016, published: September 05, 2016 
 
 
 
552 
2006; Heimark et al., 2013). This syndrome 
is frequently associated with metabolic dis-
turbances such as insulin resistance and hy-
perinsulinemia (Kotsa et al., 2009). The po-
tentiality for developing impaired glucose 
tolerance or type 2 diabetes mellitus, before 
reaching the age of 26 years, exists in 40 % 
of obese PCOS patients (Diamanti- Kandara-
kis et al., 2006). Symptoms of insulin re-
sistance such as elevated blood pressure, 
obesity, and abdominal obesity are all the 
known risk factors for the development of 
metabolic syndrome, cardiovascular disor-
ders and diabetes (Agarwal et al., 2012). The 
exact mechanism(s) of this syndrome is ob-
scure. However, insulin resistance is consid-
ered to be the main cause in the pathogenesis 
of this syndrome (Fenkci et al., 2003). It has 
been postulated that elevated insulin (hyper-
insulinemia) is important in the pathogenesis 
of endocrine abnormality in PCOS. Lower-
ing insulin levels may produce favorable re-
sults in these patients (Vargas et al., 2011). 
Despite the fact that there are no specific 
treatments available for this population, 
treatments are generally aimed at decreasing 
insulin and androgen levels. This encom-
passes drug therapy including insulin lower-
ing and anti androgen medications or oral 
contraceptives, and life style interventions 
(Douglas et al., 2006). 
 
NUTRIENTS AND PCOS  
The effects of nutrient composition of di-
et on PCOS have started to receive attention 
only recently (Rodrigues et al., 2009). De-
spite the evidence supporting an effect of 
nutrition therapy for patients with PCOS 
(O'Connor et al., 2010), little is known about 
the influence of diet composition on PCOS 
metabolic and endocrine control (Rodrigues 
et al., 2009). For individuals with PCOS, the 
dietary treatments plan focuses on macronu-
trients content. However, the focus on mi-
cronutrients also continues to be an effective 
strategy (Bernier, 2012). Obviously, it is 
necessary to improve our understanding 
about functional roles of some specific nutri-
ents in PCOS (O'Connor et al., 2010). These 
aspects will be specially discussed in this 
paper in order to provide a comprehensive 
review of the recently published in vitro and 
in vivo animal studies and also human clini-
cal trials in which the influence of novel nu-
trients such as inositol, isoflavonids, resvera-
trol, vitamin D, and PUFA (polyunsaturated 
fatty acids) on hormonal and metabolic dis-
turbances of PCOS is assessed. 
 
Inositol  
Studies using inositol are summarized in 
Table 1. 
Two isomers of inositol (myo-inositol 
and D-chiro-inositol) are mediators of insu-
lin action (Bizzarri and Carlomagno, 2014). 
Myo-inositol is a nutrient belonging to vita-
min B complex (Papaleo et al., 2009). Myo-
inositol is found in various types of foods 
(e.g. whole grains, seeds, and fruits) and also 
can be produced from glucose in the human 
body (Carlomagno and Unfer, 2011). Evi-
dence have shown that this nutrient could 
have a helpful role in decreasing the hormo-
nal profile, oxidative abnormalities, and as 
well as the metabolic factors in patients with 
PCOS, probably due to the amelioration of 
insulin resistance in these patients (Costan-
tino et al., 2009; Donà et al., 2012). In a pla-
cebo-controlled trial, women with PCOS 
were randomized to receive either oral myo-
inositol (4 g/d) plus folic acid (400 mcg/d) or 
folic acid alone for 12-16 weeks (Costantino 
et al., 2009). Results showed that myo-
inositol administration diminished the serum 
androgen levels. Moreover, this treatment 
improved the glucose tolerance and other 
metabolic profiles of these women (Costan-
tino et al., 2009). Similar results were report-
ed when the effects of myo-inositol (3 g/d) 
on hormonal profiles and insulin response 
during an oral glucose tolerance test (OGTT) 
in normal weight PCOS patients were ana-
lyzed (Genazzani et al., 2014a). Genazzani et 
al. (2008) reported that myo-inositol sup-
plementation (2 g/d) plus folic acid (200 µg/ 
d) was effective in the amelioration of plas-
ma luteinizing hormone (LH), Prolactin 
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(PRL), and testosterone levels in overweight 
PCOS patient after 12 weeks consumption, 
probably through the reduction in plasma 
insulin concentration (Genazzani et al., 
2008). The mechanism by which the myo-
inositol induces its effect is probably through 
the induction of inositolphosphoglycans 
(IPG) release (Genazzani et al., 2008). In 
fact, an IPG molecule containing D-chiro-
inositol plays a key role in activating en-
zymes that control glucose uptake and usage. 
IPG performs as a putative post-receptor 
mediator of insulin signaling pathway or as a 
second-messenger (Baillargeon et al., 2010; 
Papaleo et al., 2009). Consequently, authors 
suggested that the insulin resistance ob-
served in PCOS women is related, at least 
partially, to the defect in one of the media-
tors of insulin containing D-chiro-inositol 
(Bromberg and Edlich, 1994). Metformin 
ameliorates insulin action in PCOS patients 
through releasing D-chiro-inositol-IPG me-
diator (Galazis et al., 2011). Myo-inositol is 
the most common form of inositol, which is 
converted to D-chiro-inositol by an epi-
merase (Larner, 2002). For the first time 
Bizzarri and Carlomagno (2014) showed that 
D-chiro-inositol is reduced in the urine and 
tissues of non-insulin-dependent diabetic pa-
tients. A review examined the status of D-
chiro-inositol in animals and suggested that 
the oral supplementation of D-chiro-inositol 
may perform to bypass an absence in con-
version of myo-inoistol to d- chiro inositol. 
D-chiro-inositol administration may be ef-
fective in improving insulin resistance 
(Larner, 2002). In the study of Nestler et al. 
(1999), D-chiro-inositol taken orally (1200 
mg/d) for 6-8 weeks, reduced the serum an-
drogen levels and improved the insulin re-
sistance associated with metabolic imbalanc-
es in obese women with the PCOS. Similar 
effects were observed with the consumption 
of small amounts of D-chiro-inositol (500 
mg/d) for 12 weeks in obese hyperinsuline-
mia PCOS women (Genazzani et al., 2014b). 
Furthermore, in agreement with these find-
ings, a very recent data by Laganà et al. 
(2015) showed improved results in hormo-
nal, metabolic, endocrine and the indices of 
ovarian function in PCOS women, following 
the oral ingestion of 1 gr of D-chiro-inositol 
plus 400 mcg of folic acid for 6 months. 
Surprisingly, a study performed in 50 over-
weight women with PCOS reported that 550 
mg of myo-inositol plus 13.8 mg D-chiro-
inositol in soft gel capsule consumed twice a 
day could better restore the metabolic pa-
rameters compared to the consumption of 2 g 
of myo-inositol in powder format. This ob-
servation indicates that the combination of 
such compound in physiological blood ratio 
(40:1) could be a useful tool for nutrition 
therapy of PCOS overweight patients, due to 
the beneficial effects of these agents on alle-
viation of metabolic syndrome risk (Nordio 
and Proietti, 2012). Furthermore, the availa-
ble data support the idea that both the inosi-
tol isoforms are effective in the treatment of 
patients with PCOS. Nevertheless, myo-
inositol potentially improves the metabolic 
profile, whereas D-chiro-inositol exerts posi-
tive effects on hyperandrogenism (Pizzo et 
al., 2014). Yet, a systematic review assessing 
the effects of D-chiro-inositol on ovulation 
and/or metabolic markers in PCOS failed to 
find consistent conclusion, mostly because of 
heterogeneity in the method of each study 
and also lack of relevant trials and small 
sample sizes (Galazis et al., 2011). Finally, 
Unfer et al. (2012) performed a meta-
analysis of 6 randomized placebo–controlled 
trials which used a range of 0.2-4 g/day 
myo-inositol in PCOS patients and conclud-
ed that myo-inositol supplementation can 
decrease the levels of various hormones such 
as LH, LH/follicle stimulating hormone 
(FSH), PRL, and testosterone and improve 
the dyslipidemia by reducing insulin concen-
trations. Furthermore, authors suggested that 
4 g/day myo-inositol treatment is more effec-
tive in the treatment of entire symptom spec-
trum. Interestingly, no side effects have been 
reported by doses used in all these studies 
(Carlomagno and Unfer, 2011).  
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Table 1: Metabolic and hormonal effects of inositol in PCOS 
Author  
(year) 
Time 
frame 
Number 
of  
subjects  
Study  
population 
Intervention(s)  
(Dose) 
Results 
Costantino 
et al. (2009) 
12-16 
weeks 
42  PCOS women 1) oral myo-inositol (4 g/d) 
plus folic acid (400 mcg/d)  
2) folic acid (400 mcg/d) 
1) Serum total and free testos-
terone was decreased in myo-
inositol group. 
2) Triglyceride and total cholester-
ol were decreased in myo-inositol 
group. 
3) The area under the plasma 
insulin curve after oral glucose 
ingestion was decreased in myo- 
inositol group. 
Genazzani 
et al. 
(2014a) 
 
12 
weeks 
24 Normal weight 
PCOS women 
oral myo-inositol (3 g/d) 1) LH, LH/FSH, androstenedione 
and 17-hydroxy-progesterone 
levels reduced significantly after 
treatment. 
 2) Insulin response to OGTT was 
significantly decreased after myo-
inositol supplementation.  
3) The concentration of high-
sensitivity C-reactive protein (hs-
CRP) decreased significantly after 
myo-inositol supplementation.  
Genazzani 
et al. 
(2008) 
12 
weeks 
20 Overweight 
PCOS women 
1) oral myo-inositol (2 g/d) 
plus folic acid (200 mcg/d)  
2) folic acid (200 mcg/d) 
1) Plasma LH, PRL, and testos-
terone concentrations and LH/FSH 
were reducted significantly in myo- 
inositol group. 
2) Insulin sensitivity and HOMA 
index were improved in myo- ino-
sitol. 
Nestler et 
al. (1999) 
 
6-8 
weeks 
44 Obese PCOS 
women 
1) oral d-chiro-inositol 
(1200 mg/d) 
2) placebo  
1) Serum free testosterone was 
decreased in d-chiro-inositol group 
compared with placebo group. 
2) No significant change in glu-
cose tolerance was observed. 
4) The area under the plasma 
insulin curve after oral glucose 
ingestion was decreased in myo- 
inositol group compared with pla-
cebo group. 
Genazzani 
et al. 
(2014b)  
12 
weeks 
22 Obese PCOS 
women 
Oral d-chiro-inositol 
(500 mg/d) 
1) LH, ratio of LH to FSH and 
androstenedione levels and insulin 
response to OGTT were improved. 
Laganà et 
al. (2015) 
6 
months 
48 Woman with 
PCOS and 
chronic ovulato-
ry dysfunction 
Oral D-chiro-inositol 
(1 gr/day ) plus folic acid 
(400 mcg/day) 
1) D-chiro-inositol administration 
significantly reduced total testos-
terone, free testosterone,  D-4-
Androstenedione, 
Prolactin and HOMA index. 
2) LH and LH/ FSH ratio were 
decreased and SHBG was in-
creased.  
Nordioand 
Proietti 
(2012) 
6 
months 
50 PCOS over-
weight women 
1) myo-inositol powder 
(2 g/d) 
2) myo-inositol (550 mg) plus 
d-chiro-inositol (13.8 mg/d) 
in soft gel  
capsule twice a day 
1) Both plasma glucose and insu-
lin levels were significantly de-
creased when myo-inositol plus d- 
chiro-inositol ingested (in month 3) 
2) Serum total testosterone level 
was decreased and SHBG levels 
were increased more relevant in 
myo-inositol plus d-chiro-inositol 
group (in month 3 and in month 6) 
Pizzo et al. 
(2014)  
 
6 
months 
50 PCOS women 1) oral myo-inositol (4 g/d) 
plus folic acid (400 mcg/d)  
2) oral d-chiro-inositol(1 g/d) 
plus folic acid (400 mcg/d) 
Total testosterone, HOMA index 
and LH/FSH ratio resulted statisti-
cally significantly decreased in 
myo- inositol group compared with 
d-chiro-inositol. 
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Although, only few randomized controlled 
trials (RCTs) using small sample size have 
been conducted (Galazis et al., 2011; Unfer 
et al., 2012). Several studies have reported to 
date the positive effects of myo-inositol and 
D-chiro-inositol on clinical, metabolic, en-
docrine, hormonal, and oxidative abnormali-
ties in women with PCOS. Based on these 
observations, this naturally occurring com-
pound may represent an alternative or com-
plementary care to metformin treatment in 
PCOS patients (Donà et al., 2012). 
 
Isoflavonoids 
Studies using isoflavonoids are summa-
rized in Table 2. 
Phytoestrogens are plant derived sub-
stances and include lignins, isoflavones and 
coumestans (Bhathena and Velasquez, 
2002). The isoflavonoids such as genistein 
and daidzein, which are mostly found in leg-
umes such as soy beans and chickpeas, have 
received considerable attention in recent 2 
decades (Eden, 2012). A number of studies 
have shown improvement in insulin re-
sistance and/or glycemic control in response 
to isoflavonegenistein consumption, a re-
sponse that appears to be, at least partially, 
due to the positive effects of this agent on β-
cells function through the promotion of pro-
liferation and the inhibition of apoptosis in 
such cells (Gilbert and Liu, 2013). Hence, 
phytoestrogens rich extracts may represent a 
promising candidate for the alternative or 
complementary management of conditions 
that are related to metabolic syndrome 
(Jungbauer and Medjakovic, 2014). A quasi- 
randomized trial preformed in 146 subjects 
with PCOS revealed that 18 mg of genistein 
(twice a day) for 3 months compared with 
cellulose as a placebo could significantly de-
crease the serum concentrations of low-
density lipoprotein cholesterol (LDL-C). Al-
so, according to these results, LH, dehydro-
epiandrostrone sulfate (DHEAS), testos-
terone, and triglyceride levels were lower in 
patients after genistein consumption compar-
ing with before the supplementation indicat-
ing that genistein could be a useful tool for 
nutrition therapy of POCS patients due to the 
beneficial effects on reproductive hormonal 
levels and also the improvement of lipid pro-
files (Khani et al., 2011). These data are in 
line with the observation of Kamel (2013) 
who found significantly favorable changes in 
LH level and FSH/LH ratio after ten days 
treatment with phytoestrogen in women with 
PCOS. In contrast, in the study of Romualdi 
et al. (2008) 36 mg/d of genistein did not al-
ter the hormonal milieu and glycoinsuline-
mic metabolism in PCOS subjects. The au-
thors concluded that the major influence of 
genistien seems to be on blood cholesterol. 
Then, a controlled 2 months cross-over trial 
conducted by Forouhari et al. (2013) failed 
to show the effect of diet rich in isoflavones 
(70 g/d soy flour) on FSH, estradiol, and tes-
tosterone concentrations in women with 
PCOS as compared to control group.  
In conclusion, these data provide evi-
dences that isoflavonegenistein could repre-
sent a therapeutic strategy for the treatment 
of clinical and metabolic imbalances in 
PCOS patients. The beneficial effect was as-
sociated with the improvement of lipid pro-
file, although it was not necessarily occurred 
in hormonal milieu. Long term trials are 
needed to evaluate the effects of isoflavone 
on hormonal, oxidative, and metabolic ab-
normalities in PCOS women. 
 
Resveratrol 
Resveratrol (trans-3,5,4'-trihydroxystil-
bene) is a naturally occurring phytoalexin 
that is produced by some plants such as 
grapes, nuts and berries in response to injury 
or fungal infection (Palsamy and Subra-
manian, 2010; Svechnikov et al., 2009). 
Resveratrol is thought to have a number of 
incredible health benefits, including: antiox-
idant, anti-inflammatory, anti-cancer, anti-
aging and cardio-protection (Oskarsson et 
al., 2014; Palsamy and Subramanian, 2010; 
Svechnikov et al., 2009). 
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Table 2: Metabolic and hormonal effects of isoflavonoids in PCOS  
Author  
(year) 
Time 
frame 
Number 
of  
subjects  
Study  
population 
Intervention(s) 
(Dose) 
Results 
Khani et 
al. (2011) 
3 
months  
146  PCOS women  1) Oral genistein 
(18 mg twice/d)  
2) placebo (cellulose)  
1) LH, triglyceride, LDL, dehydroepi-
androstrone sulfate (DHEAS), and 
testosterone levels were significantly 
reduced after 3 months treatment in 
Genistein group. 
2) No significant differences in FSH 
and HDL levels were noticed.  
3) Only LDL cholesterol was de-
creased significantly in Genistein 
group compared with control group.  
Kamel 
(2013)  
 
5-10 
days 
100 Women with PCOS 1) clomiphene citrate 
(100 mg daily for 5 
days) 
2) Cimicifugaracimosa 
(20 mg daily for 10 
days) 
Significant improvement in LH level 
and FSH/LH ratio were seen in 
Cimicifugaracimosa group. 
Romualdi 
et al. 
(2008)  
6 
months 
12 Obese, hyperinsu-
linemic, and 
dyslipidemic PCOS 
patients  
genistein (36 mg/d ) 1) Phytoestrogens adminstration 
significantly improved total choles-
terol, LDL cholesterol levels.  
2) No significant affect on anthropo-
metric indexes and hormonal profiles 
were noticed.  
Forouhari 
et al. 
(2013)  
2 
months 
42 Women with PCOS  1) soy flour (70 g/d ) 
2) wheat flour  
(40 g/d) 
No significant changes in the levels 
of FSH, estradiol, and testosterone 
were noticed in the soy flour group.  
 
 
Wong et al. (2010) found that resveratrol 
increased the apoptosis of ovarian theca-
interstitial (T-l) cells and prevented the cell 
proliferation in vitro at concentration 30–
100 µM. The antiproliferative actions of 
resveratrol might be more pronounced 
among PCOS patients, whose ovarian func-
tion is disturbed as a result of excessive T-l 
cells production (Wong et al., 2010). In con-
trast with this data, Ortega et al. (2012) ob-
served minimal effects of resveratrol on the 
apoptosis of rat granulosa cells. The authors 
suggested that the discrepancy observed 
among their results obtained on granulosa 
cells, and the previous study which used the-
ca-interstitial cells could be due to the differ-
ent effects of resveratrol on different type of 
cells. Additionally, resveratrol showed that 
in vitro it could inhibit the secretion of estro-
gen and vascular endothelial growth factor 
(VEGF) in rat granulose cells (Ortega et al., 
2012). Thence, biological effects of resvera-
trol on ovarian cells that may result in 
changes of the balance between relative rati-
os of such cells and decrease of VEGF ex-
pression can have pervasive consequences in 
PCOS condition (Ortega et al., 2012).  
There is a broad range of experimental 
evidences for resveratrol as steroid hormones 
inhibitor in vitro (Ortega et al., 2012; 
Oskarsson et al., 2014; Svechnikov et al., 
2009) with several different mechanisms; at 
least in part, through the reduction of Cyp19 
mRNA expression (Ortega et al., 2012), and 
as another mechanism, suppression of StAR 
(steroidogenic acute regulatory) protein and 
cytochrome P450c17 expression (Svechni-
kov et al., 2009). Molecular mechanism(s) of 
action of resveratrol may be different, de-
pending on resveratrol concentration 
(Schmitt and Dirsch, 2009) and/or the type 
of cell (Liu et al., 2013). Ortega et al. (2014) 
indicated that the combination of resveratrol 
and simvastatin is a highly effective andros-
tenedione and androsterone production in-
hibitor in rat theca-interstitial cells compared 
to simvastatin alone. A study investigating 
the role of resveratrol in the PCOS was con-
ducted on PCOS models (Ergenoglu et al., 
2015). The administration of resveratrol 
lowered serum superoxide dismutase (SOD) 
activity and elevated glutathione peroxides 
(GPx) level. Moreover, a reduction in the 
levels of plasma anti-Mullerian hormone and 
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insulin-like growth factor 1, besides in the 
number of antral follicle was observed in 
PCOS rats. The authors concluded that due 
to its antioxidant properties resveratrol sup-
plementation had therapeutic effect on exper-
imental PCOS induced by dihydrotestos-
terone (Ergenoglu et al., 2015).  
There is evidence that resveratrol exerts 
suppressive action on insulin release in both 
in vitro and in vivo (Szkudelski, 2006, 2008). 
The insulin suppressive effect is beneficial 
for patients who suffer from exaggerated se-
cretion of insulin such as patients who have 
insulinoma or PCOS (Szkudelski, 2008). In 
disagreement with this finding, the oral ad-
ministration of resveratrol (5 mg/kg body 
weight) for 30 days in Wistar diabetic rats 
resulted in the enhancement of insulin secre-
tion and antioxidant competence in islet β 
cells compared to control rats (Palsamy and 
Subramanian, 2010). A very recent meta-
analysis of clinical trials showed significant 
advantages of resveratrol in the improvement 
of glycosylated hemoglobin (HbA1c) 
(Hausenblas, et al., 2014). Since nearly 30–
40 percent of PCOS patients have impaired 
glucose tolerance (IGT) and 7.5–10 percent 
of them are found to have type 2 diabetes 
(Sirmans and Pate, 2014), the benefits asso-
ciated with the consumption of resveratrol 
for PCOS patients with type 2 diabetes gets 
more clear. 
Collectively, this data provide evidences 
that resveratrol supplementation could repre-
sent a novel treatment for the management of 
PCOS patients mostly because of its antioxi-
dant properties (Wong et al., 2010). Indeed, 
to the best of our knowledge, there has been 
no published trial, so far, examining the in-
fluence of resveratrol on the condition asso-
ciated with PCOS outcome. However, two 
studies are registered with clinical trials reg-
istry to assess the effects of resveratrol on 
biochemical factors, reproductive as well as 
endocrine outcomes in PCOS population 
(Ortega and Duleba, 2015). Thus, future re-
search is needed to assess the resveratrol ef-
fects on PCOS symptoms. 
Vitamin D 
Studies using vitamin D are summarized 
in Table 3. 
Vitamin D deficiency (25OHD<20 ng/ 
ml) is very common in women with PCOS 
so that 67-85 % of women with PCOS have 
low levels of vitamin D (Mahmoudi et al., 
2010; Thomson et al., 2012). Vitamin D in-
sufficiency could contribute to the develop-
ment of insulin resistance and obesity 
(Tzotzas et al., 2010; Wehr et al., 2009), as 
the major features of PCOS (Wehr et al., 
2009). Besides, it has been reported that 
gene polymorphism is linked with PCOS (at 
least partially) through the role of this gene 
on insulin blood levels and insulin resistance 
(Mahmoudi, 2009). Yet, the mechanism(s) 
by which low vitamin D levels can cause in-
sulin resistance is unclear (Lerchbaum and 
Obermayer-Pietsch, 2012). In an animal 
study, it has been suggested that vitamin D 
could pose as an effective antioxidant by en-
hancing the levels of glutathione (GSH), 
SOD, and GPx and also by diminishing in 
lipid peroxidation, and notably, the antioxi-
dant effect of vitamin D was much greater 
than that the effect observed for vitamin E 
(Sardar et al., 1995). In human study, Tarcin 
et al. (2009) suggested that vitamin D could 
act as a potent antioxidant through the inhi-
bition of oxidative stress and lipid peroxida-
tion. Given that chronic inflammation and 
oxidative stress play causative roles in path-
ogenesis of insulin resistance (Ceriello and 
Motz, 2004) and on the other hand, vitamin 
D has effects on insulin levels and expres-
sion of insulin receptor, and also inhibits in-
flammation (Tzotzas et al., 2010) and oxida-
tive stress (Lerchbaum and Obermayer-
Pietsch, 2012). For the first time, Kotsa et al. 
(2009) showed that the consumption of Al-
phacalcidol (1-a-hydroxyvitamin D3) 1 
µg/day for 3 months in 15 obese women with 
PCOS and insulin resistance, produced an 
effect on the first phase insulin stimulation, 
indicating that vitamin D3 could be effective 
in the treatment of PCOS. Rashidi et al. 
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Table 3: Metabolic and hormonal effects of vitamin D in PCOS  
Author  
(year) 
Time 
frame 
Number 
of  
subjects  
Study  
population 
Intervention(s)  
(Dose) 
Results 
Kotsa et al. 
(2009)  
 
3 
months 
15 Obese women 
with PCOS 
Oral alphacalcidol (1-a 
hydroxyvitamin D3) (1 
mg/d) 
1) Vitamin D significantly increased 
the first-phase insulin secretion 
after the treatment interval. 
2) Vitamin D significantly increased 
HDL level and decreased TG level. 
Rashidi et al. 
(2009)  
 
3 
months 
60 Infertile PCOS 
patients 
1) calcium (1000 mg/d) 
plus vitamin D (400 IU/d) 
2) calcium (1000 mg/d) 
plus vitamin D (400 IU/d 
plus) metformin  
(1500 mg/d) 
3) metformin (1500 mg/d) 
Follicles maturation was improved 
in calcium–vitamin D plus metfor-
min group than either group.  
Firouzabadi 
et al. (2012)  
 
6 
months 
100 Infertile PCOS 
women 
1) metformin (1500 mg/d) 
2) metformin (1500 mg/d) 
plus calcium (1000 mg/d) 
and vitamin D (100000 
IU) 
Follicular response was relatively 
higher in metformin plus vitamin D 
and calcium group compared with 
metformin alone but the differ-
ences were not significant. 
Ardabili et al. 
(2012)  
2 
months 
50 Women with 
PCOS and a 
vitamin D defi-
ciency 
1) vitamin D3 (50000 IU/ 
every 20 days) 
2) placebo  
The fasting serum insulin and glu-
cose levels and the insulin sensitiv-
ity and HOMA levels did not 
change significantly by the treat-
ment.  
Raja-Khan et 
al. (2014)  
12 
weeks 
22  Women with 
PCOS 
1) vitamin D3  
(12000 IU/d) 
2) placebo 
No significant differences in fasting 
insulin, fasting glucose, QUICKI 
and HOMA-IR between two treat-
ment groups were noticed. 
 
 
 
(2009) determined that combined consump-
tion of metformin 1500 mg/d plus calcium 
1000 mg/d and vitamin D 400IU/d was more 
effective in the treatment of PCOS, as indi-
cated by the maturation of follicles, than ei-
ther compound alone. Similarly, Firouzabadi 
et al. (2012) reported that in 100 infertile 
PCOS women, following the intake of met-
formin 1500 mg/d plus calcium 1000 mg/d 
and vitamin D 100000 IU/month for 6 
months, body mass index (BMI) was signifi-
cantly reduced and follicle maturation and 
hyperandrogenism was improved in compar-
ison with those treated with metformin 1500 
mg/d alone. Therefore, abnormal calcium 
homeostasis is associated with clinical mani-
festations of PCOS including follicular arrest 
and the menstruation disorders (Thys-Jacobs 
et al., 1999). Serum 25–hydroxy vitamin D 
level is lower in obese PCOS women 
(Yildizhan et al., 2009) and associates in-
versely with insulin resistance (Tzotzas et 
al., 2010). On the other hand, moderate 
weight loss can increase 25 hydroxy vitamin 
D levels and this raise is correlated with ben-
eficial effects on insulin sensitivity (Tzotzas 
et al., 2010). Hence, life style interventions 
such as weight management program 
(Tzotzas et al., 2010) and vitamin D admin-
istration can be useful to treat obese PCOS 
patients (Yildizhan et al., 2009) and PCOS 
women with low 25(OH)D serum levels 
(Brzozowska and Karowicz-Bilińska, 2013). 
Finally, a very recent systematic review ex-
amined the effects of vitamin D on metabolic 
abnormalities and suggested an inverse asso-
ciation between these two parameters in 
women suffering from PCOS (Krul-Poel et 
al., 2013). Yet, some studies failed to sup-
port these results; Ardabili et al. (2012) 
demonstrated that low dose vitamin D 
(50000 IU/every 20 day) did not improve 
insulin resistance after 2 months supplemen-
tation in women with PCOS and vitamin D 
deficiency. Raja-Khan et al. (2014) reported 
that high dose vitamin D (12000 IU/d) sup-
plementation did not improve insulin sensi-
tivity in PCOS patients. Taken together, fur-
ther well designed clinical studies are needed 
to find out the effect of vitamin D supple-
mentation in treating PCOS patients (Krul-
Poel et al., 2013; Thomson et al., 2012). 
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PUFA 
Studies using PUFA are summarized in 
Table 4. 
Dietary intake of PUFA, counting n-3 
and n-6 fatty acids, was positively correlated 
with GPx activity (Chen et al., 2003). It 
seems that PUFA is involved in the suppres-
sion of apoptosis which is responsible for 
pathophysiology of PCOS (Ghasemzadeh et 
al., 2013). Moreover, it is interesting to note 
that PUFAs improve the action of insulin in 
peripheral target organs and reduce insulin 
secretion from ß-cells of the pancreatic. In 
addition, PUFA and their products such as 
15-dexyprostaglydin J2 seem to act as natural 
ligands for Peroxisome Proliferator-Activat-
ed Receptor (PPAR) gamma. Due to the 
treatment application of synthetic PPAR 
gamma ligand used in insulin resistance 
therapy in PCOS population, it can be as-
sumed that dietary PUFAs may play a role in 
the reduction of insulin resistance (Kasim-
Karakas et al., 2004). However, one research 
evaluated the effects of PUFA rich diet (48 g 
walnuts/800 kcal of total calorie intake) in 
17 PCOS patients after a 3 months habitual 
diet. No change in plasma testosterone nor 
LH and FSH levels was detected after 6 
months (Kasim-Karakas et al., 2004). Higher 
circulating n-6 and higher ratio of n-6 to n-3 
are shown to be associated with higher plas-
ma androgen levels in PCOS patients, and 
testosterone plasma levels reduced by n-3 
PUFA administration (Phelan et al., 2011). 
Omega 3 PUFA can be considered as an im-
portant PUFA involved in regulating insulin 
production and action, as well as improving 
inflammatory processes (Vargas et al., 
2011). Oral supplementation of n-3 PUFA 
plus lower carbohydrate feeding has been 
shown to improve PCOS in rats; with a de-
crease in levels of testosterone and increase 
in levels of FSH (Ouladsahebmadarek et al., 
2014). In a study by Mohammadi et al. 
(2012) it was shown that supplementation 
with long chain omega-3 fatty acid (EPA and 
DHA) had beneficial effects on cardiovascu-
lar risk through the improvement of antioxi-
dant levels, insulin resistance and lipid pro-
file without changing the body weight in 
women with PCOS. In another study with 78 
overweight and obese PCOS patients, omega 
n-3 fatty acid (3 g/day) consumption de-
creased testosterone concentration compared 
with placebo, while no significant changes in 
free androgen index (FAI) and sex hormone 
binding protein (SHBG) levels occurred in 
either treatments (Nadjarzadeh et al., 2013). 
Likewise, in a study with PCOS women, the 
results supported the efficacy of omega-3 
supplementation (1500 mg/day) in reducing 
insulin and HOMA levels and improving 
hormonal profile after 6 months of treatment 
(Oner and Muderris, 2013). In a study by 
Cussons et al. (2009) supplementation at 
higher doses (omega-3 PUFA 4 g/d) in 25 
women with PCOS reduced levels of 
triglysecride and hepatic fat. Moreover, a 
recent review concluded that omega-3 seems 
to improve dyslipidemia and insulin sensitiv-
ity in PCOS patients by producing anti-
inflammatory and antioxidant activity 
(Macut et al., 2012).  
However, the results of Kuzmanov study 
(2009) showed that the consumption of ome-
ga-3 fatty acids did not have a significant 
impact on the reproductive or metabolic ab-
normalities of PCOS after 3 months of ther-
apy. 6 week of treatment with a daily long 
chain omega-3 PUFA applying a dose of 
3.5 g in PCOS population didn’t affect insu-
lin levels and fasting glucose (Vargas et al., 
2011). For the first time, Dunaif et al. (1995) 
suggested that excessive insulin receptor ser-
ine phosphorylation is responsible for de-
fects in insulin action, and also shows that 
serine phosorylation of IRS-1 is actually in-
creased in women with PCOS. It is tempting 
to speculate that PCOS individuals couldn’t 
reverse this abnormality, and omega-3 PUFA 
couldn’t accordingly improve insulin
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Table 4: Metabolic and hormonal effects of PUFA in PCOS  
Author  
(year) 
Time frame Number 
of  
subjects  
Study  
population 
Intervention(s) 
(Dose) 
Results 
Kasim-
Karakas et 
al. (2004) 
 
3 months 
control and 
then 
3 months 
intervention  
17 PCOS women Diet rich in PUFA  
(48 g walnuts/800 
kcal of total calories 
intake) 
1) PUFA rich in diet significantly 
increased the fasting glucose 
and AUC for glucose. 
2) The fasting serum insulin and 
AUC for insulin did not change 
significantly during the study. 
3) After 3 months PUFA – rich 
diet ingestion did not alter FSH, 
LH, testosterone, free testos-
terone, SHBG and ehydroepi-
androsterone sulfate levels. 
Mohammadi 
et al. (2012)  
 
8 weeks 61 Overweight or 
obese PCOS 
women 
1) omega-3 (4 g/day)  
2) placebo 
Ingestion of omega n-3 fatty acid 
significantly increased serum 
HDL and decreased total choles-
terol, LDL cholesterol, TG, glu-
cose, insulin and HOMA com-
pared with placebo. 
Nadjarzadeh 
et al. (2013) 
 
8 weeks 78 Overweight/obese 
women with 
PCOS 
1) omega-3 (3 g/day)  
2) placebo 
1) Testosterone levels decreased 
significantly in the omega-3 
group compared with placebo.  
2) Serum SHBG and FAI concen-
tration did not alter in either 
group during the trial. 
Oner and 
Muderris 
(2013)  
 
6 months 45 Non-obese PCOS 
women 
omega-3 (1.5 g/day) 1) Insulin levels and HOMA were 
decreased significantly, with no 
change in glucose levels. 
2) The levels of testosterone and 
LH decreased while SHGB con-
centration increased significantly. 
Cussons et 
al. (2009) 
 
8 weeks 25 PCOS women 1) omega-3 (4 g/d) 
2) placebo 
Ingestion of omega n-3 fatty acid 
significantly decreased liver fat 
content and triglyceride levels 
compared with placebo. 
Kuzmanov 
(2009)  
3 months 12 PCOS women EPA and DHA (1 g/d) 
 
1) No significant difference was 
observed in fasting plasma glu-
cose levels. 
 2) Fasting insulin concentration 
and HOMA index decreased, but 
the differences were not signifi-
cant. 
3) Total serum testosterone, 
estrogen, FAI, LH, FSH and the 
ratio of LH to FSH did not alter 
with omega-3 ingestion.  
Vargas et al. 
(2011) 
 
6 weeks 51 PCOS women 1) Fish oil (3.5 g/d) 
2) Flaxseed oil  
(3.5 g/d) 
3) Soybean oil  
(placebo)  
Serum fasting glucose, insulin 
levels did not alter in either group 
during the study. 
Areas under the curve (AUC) 
 
 
resistance (Vargas et al., 2011). However, it 
remains a need to conduct a comparative 
study to evaluate the contradictory effects of 
n-3 PUFA on PCOS and healthy control 
women (Vargas et al., 2011). 
Although it appears that omega-3 fatty 
acids may improve metabolic profiles and 
hormonal outcomes in PCOS patients, not all 
studies have supported the efficiency of 
omega-3 PUFA. For example, its effect on 
insulin action is vague. Prior to be recom-
mended, more research needs to be explored 
in this specific field.  
 
CONCLUSION 
Since oxidative stress, metabolic, hor-
monal and endocrine imbalance has been 
implicated in the development of PCOS, an-
tioxidant agents and nutrients that improve 
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such abnormality have the potential to re-
duce the risk of this syndrome. Findings of 
different several studies suggest that the nu-
trients are not equally effective in improving 
hormonal and metabolic disturbances of 
PCOS. As an example, among the nutrient 
studies in PCOS, inositol has shown the most 
promise. Yet, PUFA administration had been 
less effective to improve hormonal imbal-
ances in such patients. The combined effects 
of specific nutrients in PCOS women need to 
be investigated in future studies. Finally, ad-
ditional researches using antioxidants inter-
ventions such as vitamin E, vitamin C, and 
lycopene are warranted in PCOS patients.  
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